Cystadenocarcinoma - 15 Studies Found

Active, not recruiting : Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
:
  • Borderline Ovarian Mucinous Tumor
  • Ovarian Mucinous Cystadenocarcinoma<
    : 2010-03-04
    :
    • Biological: Bevacizumab Given

Terminated : Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
:
  • Adenocarcinoma of the Pancreas
  • Adenocarcinoma of the Stomach
  • Drug: veliparib Given PO
Completed : Papillary Serous Carcinoma of the Endometrium
: Endometrial Cancer
: 2007-08-09
:
  • Drug: Paclitaxel 50 mg/m^2 IV

Completed : A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma
: Uterine Cancer
: 2005-10-03
:
  • Drug: Carboplatin and Paclitaxel and Pelvic Radiation Therapy

Completed : Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
: Uterine Cancer
: 2007-07-23
:
  • Drug: Imatinib Mesylate

Not yet recruiting : Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer
:
  • Endometrial Serous Adenocarcinoma
  • Stage IIIA Uterine Corpus Can
    : 2014-04-10
    :
    • Drug: Paclitaxel Given IV
Recruiting : To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers
:
  • Pancreatic Adenocarcinoma Metastatic
  • Ovarian Serous Adenocarcinoma : 2014-07-01
    : Drug: Plerixafor A continuous 7 day intravenous infusion, starting at a dose of 20 ug/kg/hr, and subsequ
Completed : Phase II ABT-888 With Cyclophosphamide
:
  • Ovarian Cancer
  • Primary Peritoneal Cancer
  • Drug: ABT-888 PARP enzymes are
Recruiting : Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
:
  • Micropapillary Serous Carcinoma
  • Ovarian S
    : 2014-03-28
    :
    • Other: Laboratory Biomarker Analysis

Completed : Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer
:
: 2024-10-31
Next >>>